TipRanks
Advertisement
Advertisement
Abeona Therapeutics Updates Investor Presentation at Conference
PremiumCompany AnnouncementsAbeona Therapeutics Updates Investor Presentation at Conference
4d ago
Abeona Therapeutics Earnings Call Highlights ZEVASKYN Ramp
Premium
Company Announcements
Abeona Therapeutics Earnings Call Highlights ZEVASKYN Ramp
25d ago
Abeona Buy Rating Reaffirmed as Commercial Momentum Builds and $20 Price Target Remains Unchanged
Premium
Ratings
Abeona Buy Rating Reaffirmed as Commercial Momentum Builds and $20 Price Target Remains Unchanged
26d ago
Abeona’s New Phase 4 Wound Study: What ABEO Investors Should Watch
PremiumCompany AnnouncementsAbeona’s New Phase 4 Wound Study: What ABEO Investors Should Watch
1M ago
Abeona Therapeutics: CMS Reimbursement Catalyst Supports ZEVASKYN Uptake and Unchanged $20 Price Target
Premium
Ratings
Abeona Therapeutics: CMS Reimbursement Catalyst Supports ZEVASKYN Uptake and Unchanged $20 Price Target
1M ago
Abeona Therapeutics activates Cincinnati Children’s as treatment center
Premium
The Fly
Abeona Therapeutics activates Cincinnati Children’s as treatment center
2M ago
Abeona Therapeutics Updates Investor Presentation Under Regulation FD
PremiumCompany AnnouncementsAbeona Therapeutics Updates Investor Presentation Under Regulation FD
3M ago
Abeona Advances ABO-701 T-Cell Therapy Toward IND
Premium
Company Announcements
Abeona Advances ABO-701 T-Cell Therapy Toward IND
4M ago
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum
Premium
Company Announcements
Abeona Therapeutics Highlights Strong ZEVASKYN Launch Momentum
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100